Trials / Completed
CompletedNCT00171483
Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- —
Summary
Study to assess the effects of tegaserod added to PPI therapy in the resolution of heartburn and regurgitation in patients with incomplete relief from PPIs .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tegaserod |
Timeline
- Start date
- 2004-01-01
- Completion
- 2005-04-01
- First posted
- 2005-09-15
- Last updated
- 2008-01-28
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00171483. Inclusion in this directory is not an endorsement.